Valuation check: TCRT's profit margin is -133666.67%, below the Healthcare sector average of 13.71%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Alaunos Therapeutics (TCRT) currently reports a profit margin of -133666.67% as of June 2026. That compares with -66550.0% in the prior-year period — down 100.9% year over year. That is below the Healthcare sector average of 13.71%. Use the charts on this page to explore Alaunos Therapeutics's profit margin history and peer comparisons.
Alaunos Therapeutics's profit margin decreased from -66550.0% to -133666.67% — a 100.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Alaunos Therapeutics's profit margin of -133666.67% is lower than the Healthcare sector average of 13.71%. That is roughly 974997.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Alaunos Therapeutics's current -133666.67% should be judged against Healthcare norms (sector average: 13.71%) and against TCRT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -133666.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.71%. From there, open related valuation or income-statement pages for Alaunos Therapeutics, and consider following TCRT for alerts when major investors trade the stock.